Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic ...

AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...

Resmetirom is a medication approved by the FDA to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with ...

EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...

PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted full qualification for ...

For the first time, the European Medicines Agency has recognized AI software for the diagnosis of fatty liver hepatitis as ...

The result suggests that the protein made by the gene, known as Nwd1, and other molecules it interacts with could be ...